@FiercePharma: Top-read on FierceVaccines yesterday: Does Pfizer still need AstraZeneca's vaccines business? Story | Follow @FiercePharma
@EricPFierce: CPhI Worldwide will host #CPhIChat to debate the future of pharma for those of you who want a piece of that. Release | Follow @EricPFierce
@CarlyHFierce: Pfizer's C. diff vaccine gains on Sanofi with FDA fast-track nod. Story | Follow @CarlyHFierce
> Pfizer ($PFE) and Protalix BioTherapeutics ($PLX) have won FDA approval for pediatric use of Elelyso for long-term enzyme replacement therapy for Type 1 Gaucher disease. Release
> Sources say Johnson & Johnson ($JNJ) is looking for buyers for stentmaking Cordis unit. Story
> Japan's Otsuka Pharmaceutical has struck a deal to buy Brazilian health food group Jasmine Alimentos. Story
> Daiichi Sankyo said it has a deal to sell in Japan, the hepatitis B vaccine Bimmugen, which was developed by The Chemo-Sero-Therapeutic Research Institute. Announcement
Medical Device News
@FierceMedDev: New imaging system uses biomarker to guide brain cancer surgery. More | Follow @FierceMedDev
@VarunSaxena2: Between new Brain project initiative and 2 recent $COV buys + $BSX's buy of Bayer's devices, peripheral devices are officially a thing. | Follow @VarunSaxena2
@MichaelGFierce: Organic nanoparticles offer 'complete package' against cancer: delivery and imaging. Article | Follow @MichaelGFierce
> Bayer's startup accelerator funds five device, healthcare app companies. Story
> Covidien acquires Sapheon ahead of FDA approval for vein adhesive. More
Biotech News
@FierceBiotech: Band of West Coast biotech insiders pushes oral anticoagulant to PhIII. Article | Follow @FierceBiotech
@JohnCFierce: The EuroBiotech report: Ex-Shire exec starts at Cortendo, Innate gets orphan nod, Ablynx trims in preclinical. Story | Follow @JohnCFierce
@EmilyMFierce: Canadian Immunovaccine reports positive preclinical data for Ebola vaccine. More | Follow @EmilyMFierce
> ThromboGenics spins out cancer R&D, scales down staff amid lackluster Jetrea sales. Article
> Booming Gilead blueprints an overhaul of its campus. Item
And Finally... South Africa's Aspen Pharmacare reported that earnings per share excluding one-time items rose 26% for its year ended June 30. Report